Limitations: This study excluded patients with comorbidities such as diabetes and
kidney impairment. As these are common disease states, this decision limits the
extrapolation of the study data to many populations. Not all patients (305 out of 489) had
culture-confirmed dermatophyte infections. This could diminish efficacy of both
products as they could potentially be treating infection that are not fungal and therefore
untreatable by these means. 511 patients entered this study; however, only 500 were used
for safety analysis. Dropouts are not mentioned, and number of patients in efficacy tables